Latest
Imaging Mass Cytometry Reveals Prognostic Immune Phenotypes in DLBCL
Durvalumab Adds No Benefit to Single-Agent Ibrutinib in FL, DLBCL
Modeling Lost Income and Life Expectancy Due to Sickle Cell Disease
Outcomes Improved for Patients With AML and MDS Receiving Treosulfan/Fludarabine vs Busulfan/Fludarabine Conditioning Prior to HSCT
Even Slight Delays in CAR-T Therapy Administration May Increase Overall Mortality Rates
Monitoring Weight in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
Many Patients Lack Knowledge of Potential Interactions Between Apixaban, Over-the-Counter Products
Quality of Life With Busulfan and Fludarabine Compared With Busulfan and Cyclophosphamide
Response-Adapted Intensification in Multiple Myeloma After Suboptimal Response to Induction
RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera
Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia
Nurse Practitioner-Led Rapid Diagnosis Clinic May Reduce Time to Diagnosis in Lymphoma
Featured Content
Updated Guidance on Managing Bleeding and Surgery on Antiplatelet Therapy
Antiplatelet therapy is used to manage cardiovascular events but can lead to increased risk for bleeding events both mild and severe.
Can CAR-T Be Optimized for Multiple Myeloma?
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Resting vs Activated Platelets: Why Knowing the Difference Makes Financial Sense
Transfusing activated platelets can increase the number of transfusions required and thus lead to additional costs compared with transfusing resting platelets.
Treating Venous Thromboembolism in Patients With Cancer: 2019 Clinical Practice Guidelines
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
